Kaléo

Executive Summary

Kaléo is a global leader in drug-device combinations, specializing in innovative auto-injector technologies for emergency and urgent medical needs. Founded in 2011 and headquartered in Richmond, Virginia, the company is renowned for its patient-centric, easy-to-use products such as EVZIO (naloxone) for opioid overdose and AUVI-Q (epinephrine) for severe allergic reactions. These products are designed to empower patients and first responders with reliable, life-saving solutions that can be administered quickly in critical situations. With a focus on enhancing medication adherence and safety, Kaléo has established itself as a key player in the auto-injector market. Looking ahead, Kaléo continues to expand its pipeline and explore new therapeutic areas where its drug-device platform can make a significant impact. The company is actively pursuing additional FDA approvals and label expansions for existing products, as well as developing next-generation auto-injectors with improved usability and connectivity features. Given its strong commercial presence and ongoing innovation, Kaléo is well-positioned to capture further market share in the growing auto-injector space, driven by increasing demand for home-based and emergency treatments.

Upcoming Catalysts (preview)

• Q3 2026FDA approval for over-the-counter (OTC) switch of naloxone auto-injector70% success
• TBDLaunch of new auto-injector for a different emergency indication (e.g., glucagon for hypoglycemia)50% success
• TBDStrategic partnership or licensing deal with a pharmaceutical company for drug-device combination60% success